Themed “Enabling cell and gene therapies for Asia”, the inaugural Singapore Cell and Gene Therapy Conference 2023 was jointly organised by the Advanced Cell Therapy and Research Institute, Singapore (ACTRIS), Agency for Science, Technology and Research (A*STAR)’s Institute of Molecular and Cell Biology (IMCB) and SingHealth Duke-NUS Cell Therapy Centre (SDCT).
Held on 4-5 August 2023, this hybrid Conference was attended by more than 400 clinicians, researchers, manufacturing experts, and industry players who came together to showcase ground-breaking research and development (R&D) and share practical insights into the curative roles of cell and gene therapies (CGTs).
In conjunction with the conference, Guest-of-Honour Minister for Health Ong Ye Kung also officiated the launch of ACTRIS’ new 2,000 sqm cell therapy manufacturing facility, which is expected to play a pivotal role in shaping the next era of CGT manufacturing and making a positive impact on economic outcomes in Singapore and beyond.
Deloitte is proud to support this significant initiative as its Knowledge Partner. In this post-event report, we will provide a concise summary of the highlights at the Singapore Cell and Gene Therapy Conference 2023 and our observations regarding the conference proceedings.